Importance of circulating tumor cells in newly diagnosed colorectal cancer

van Dalum,Guus; Stam,Gerrit-Jan; Scholten,Loes F.A.; Mastboom,Walter J.B.; Vermes,Istvan; Tibbe,Arjan G.J.; De Groot,Marco R.; Terstappen,Leon W.M.M.

doi:10.3892/ijo.2015.2824

Importance of circulating tumor cells in newly diagnosed colorectal cancer

Authors:
- Guus van Dalum
- Gerrit-Jan Stam
- Loes F.A. Scholten
- Walter J.B. Mastboom
- Istvan Vermes
- Arjan G.J. Tibbe
- Marco R. De Groot
- Leon W.M.M. Terstappen
View Affiliations

Affiliations: Department of Medical Cell BioPhysics, University of Twente, Enschede, The Netherlands, Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands, Department of Surgery, Medisch Spectrum Twente, Enschede, The Netherlands, Department of Laboratory Medicine, Medisch Spectrum Twente, Enschede, The Netherlands
Published online on: January 9, 2015 https://doi.org/10.3892/ijo.2015.2824
Pages: 1361-1368

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Presence of circulating tumor cells (CTC) is associated with poor prognosis in patients with metastatic colorectal cancer (CRC). The present study was conducted to determine if the presence of CTC prior to surgery and during follow‑up in patients with newly diagnosed non-metastatic CRC can identify patients at risk for disease recurrence. In a prospective single center study 183 patients with newly diagnosed non-disseminated CRC, scheduled for surgery, were enrolled and followed-up for a median of 5.1 years. CTC were enumerated with the CellSearch system in 4 aliquots of 7.5 ml of blood before surgery and at several time-points during follow-up after surgery. The results showed that ≥1 CTC/30 ml of blood were detected in 44 (24%) patients before surgery. Patients with CTC before surgery had a significant decrease in recurrence-free survival (RFS, log-rank test p=0.014) and colon cancer related survival (CCRS, p=0.002). The 5-year RFS dropped from 75 to 61% and the 5-year CCRS from 83 to 69% for patients with CTC before surgery. The presence of CTC and positive lymph nodes remained significant factors in multivariate analysis for recurrence-free survival (RFS). Surprisingly, the presence of CTC weeks after surgery was not significantly associated with RFS and CCRD whereas CTC 2-3 years after surgery was again significantly associated with RFS and CCRD. The presence of CTC in patients with stage I-III CRC before surgery is associated with a significant reduction in RFS and CCRS. These findings suggest a role of CTC detection to assess which patients need adjuvant treatment.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Shah S, Haddad R and Al-Sukhni W: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 202:468–475. 2006. View Article : Google Scholar : PubMed/NCBI
3	Safi F and Beyer HG: The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev. 17:417–424. 1993.PubMed/NCBI
4	André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3016. 2009. View Article : Google Scholar : PubMed/NCBI
5	Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
6	Cristofanilli M and Budd G: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Engl J Med. 351:781–791. 2004. View Article : Google Scholar
7	De Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
8	Cohen SJ, Punt CJA, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008. View Article : Google Scholar : PubMed/NCBI
9	Franken B, de Groot MR, Mastboom WJB, Vermes I, van der Palen J, Tibbe AGJ and Terstappen LWMM: Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 14:R1332012. View Article : Google Scholar : PubMed/NCBI
10	van Dalum G, van der Stam GJ, Tibbe AGJ, et al: Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol. 46:407–413. 2015.
11	Liu MC, Shields PG, Warren RD, et al: Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 27:5153–5159. 2009. View Article : Google Scholar : PubMed/NCBI
12	Pierga JY, Hajage D, Bachelot T, et al: High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 23:618–624. 2012. View Article : Google Scholar
13	Tol J, Koopman M, Miller MC, et al: Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 21:1006–1012. 2010. View Article : Google Scholar
14	Lucci A, Hall CS, Lodhi AK, et al: Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 13:688–695. 2012. View Article : Google Scholar : PubMed/NCBI
15	Bidard FC, Mathiot C, Delaloge S, et al: Single circulating tumor cell detection and overall survival in non-metastatic breast cancer. Ann Oncol. 21:729–733. 2010. View Article : Google Scholar
16	Martín M, Custodio S, de Las Casas MLM, et al: Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. Oncologist. 18:917–923. 2013. View Article : Google Scholar : PubMed/NCBI
17	https://www.oncoline.nl. Integr Kankercent Ned. 2013
18	R Core Team. R: A Language and Environment for Statistical Computing. 2013
19	Jueckstock JK, Rack BK, Zwingers T, Hepp PGM, Schneeweiss A, Beckmann MW, Lichtenegger W, Sommer HL, Pantel K, Tesch H, Forstbauer H, Lorenz R, Rezai M, Neugebauer JK, Andergassen U, Friese K and Janni W: Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer: results of the German SUCCESS trial. J Clin Oncol. 29(Suppl): 10332011.
20	Pierga JY, Bidard FC, Mathiot C, et al: Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 14:7004–7010. 2008. View Article : Google Scholar : PubMed/NCBI
21	Coumans FA, Siesling S and Terstappen LW: Detection of cancer before distant metastasis. BMC Cancer. 13:2832013. View Article : Google Scholar : PubMed/NCBI
22	Cohen SJ, Punt CJ, Iannotti N, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 20:1223–1229. 2009. View Article : Google Scholar : PubMed/NCBI
23	Tibbe AGJ, Miller MC and Terstappen LWMM: Statistical considerations for enumeration of circulating tumor cells. Cytometry A. 71:154–162. 2007. View Article : Google Scholar : PubMed/NCBI
24	Thorsteinsson M, Soletormos G and Jess P: Low number of detectable circulating tumor cells in non-metastatic colon cancer. Anticancer Res. 31:613–617. 2011.PubMed/NCBI
25	Sastre J, Maestro ML, Puente J, et al: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 19:935–938. 2008. View Article : Google Scholar : PubMed/NCBI
26	Hiraiwa K, Takeuchi H, Hasegawa H, et al: Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 15:3092–3100. 2008. View Article : Google Scholar : PubMed/NCBI
27	Gazzaniga P, Gianni W and Raimondi C: Circulating tumor cells in high-risk nonmetastatic colorectal cancer. Tumor Biol. 34:2507–2509. 2013. View Article : Google Scholar
28	Coumans FA, Ligthart ST, Uhr JW and Terstappen LWMM: Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res. 18:5711–5718. 2012. View Article : Google Scholar : PubMed/NCBI
29	Pantel K, Denève E, Nocca D, et al: Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58:936–940. 2012. View Article : Google Scholar
30	Wind J, Tuynman JB, Tibbe AG, Swennenhuis JF, Richel DJ, van Berge Henegouwen MI and Bemelman WA: Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. Eur J Surg Oncol. 35:942–950. 2009. View Article : Google Scholar : PubMed/NCBI
31	Bednarz-Knoll N, Alix-Panabières C and Pantel K: Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 13:2282011. View Article : Google Scholar : PubMed/NCBI